Negative effect of immunosuppressive therapy in the performance of the QuantiFERON Gold In-Tube test in patients with immune-mediated inflammatory diseases
Autor: | Juan Carlos Rodríguez, Catalina Robledano, Mar Masiá, C. López, Francisco J. Navarro-Blasco, Jaime Matarredona, José Ramos, Félix Gutiérrez, Mariana Fe García-Sepulcre, Sergio Padilla |
---|---|
Rok vydání: | 2013 |
Předmět: |
Adult
Male medicine.medical_specialty Adolescent Tuberculin Gastroenterology Inflammatory bowel disease Sensitivity and Specificity General Biochemistry Genetics and Molecular Biology QuantiFERON Young Adult Latent Tuberculosis Psoriasis Internal medicine medicine Humans Prospective Studies Prospective cohort study Aged Latent tuberculosis business.industry Tuberculin Test Tumor Necrosis Factor-alpha General Medicine Middle Aged medicine.disease Immune System Diseases Rheumatoid arthritis Immunology Immune-mediated inflammatory diseases Female business Immunosuppressive Agents Interferon-gamma Release Tests |
Zdroj: | CLIN EXP MED r-FISABIO: Repositorio Institucional de Producción Científica Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO) CLINICAL AND EXPERIMENTAL MEDICINE r-FISABIO. Repositorio Institucional de Producción Científica instname |
ISSN: | 1591-8890 |
Popis: | To compare the tuberculin skin test (TST) and QuantiFERON-TB Gold In-Tube test (QFG) for the detection of latent tuberculosis infection among patients with immune-mediated inflammatory diseases before antitumor necrosis factor-α therapy. A prospective study including 153 consecutive patients with rheumatoid arthritis (n = 53), psoriasis (n = 45), inflammatory bowel disease (n = 25), and spondyloarthropathy (n = 22) were included. QFG and TST were performed simultaneously. TST was positive in 43/153 (28.1 %) patients. QFG (cutoff ≥ 0.35 IU/ml) was positive in 15/153 (9.8 %) patients, and indeterminate in one (0.7 %). QFG (cutoff ≥ 0.10 IU/ml) was positive in 25/153 (16.3 %). 59.5 % of the patients were on immunosuppressive therapy at the time of testing. There was a significant difference in the rate of positive QFG between patients with and without immunosuppressive therapy after adjustment for age and gender (cutoff ≥ 0.35 IU/ml, 4.6 vs. 17.4 %; adjusted odds ratio [AOR], 0.2; 95 % confidence interval [CI], 0.06–0.8; p = 0.03 and cutoff ≥ 0.10 IU/ml, 11.2 vs. 24.2 %; AOR, 0.3; 95 % CI, 0.1–0.93; p = 0.04). Agreement between TST and QFG was ‘fair’ (κ = 0.354 and κ = 0.365, for cutoffs ≥ 0.35 and ≥0.10 IU/ml, respectively). Among patients without immunosuppressive therapy, the concordance between TST and QFG was ‘moderate-substantial’ (κ = 0.593 and κ = 0.690, for cutoffs ≥ 0.35 IU/ml and ≥0.10 IU/ml, respectively). By contrast, among patients on immunosuppressive therapy the concordance was ‘poor’ (κ = 0.085; κ = 0.041, respectively). Immunosuppressive therapy affects negatively QFG performance. In patients with immune-mediated inflammatory diseases, QFG may have a limited role for screening of latent tuberculosis infection. |
Databáze: | OpenAIRE |
Externí odkaz: |